In the Amalus drug discovery program (StepStone), we pursue the establishment of a spin-off company to progress cell-selective inhibitors to clinical trials. This ConcepTT project will increase the IP and investment value of the program.

Our inhibitors possess unique features with respect to competition and represent a first-in-class opportunity.

As single agents, our molecules inhibit metastasis in vivo. In the StepStone project, we now focus on growth and metastasis in combination with anti-proliferatives.

Recent data shows that our inhibitors cause remarkable cellular effects in vivo, which may answer unmet needs in two additional applications:

• Combination with checkpoint inhibitors: our compounds may render additional indications responsive to immunotherapy.
• Fibrosis: they may constitute a well-tolerated solution to revert progression.

The Stepstone funding does not cover these new opportunities. This ConcepTT project, therefore, aims to generate in vivo proof-of-mechanism and efficacy for pulmonary fibrosis (stand-alone) and breast cancer (combined with a checkpoint inhibitor).